> Before Minority Interest and Income Taxes 261 (337) 3,534 2,400
Provision/(Benefit) for income taxes 177 (183) 803 538
Minority interest, net of taxes 217 16 763 440
Net (Loss)/Earnings from Continuing
Operations (133) (170) 1,968 1,422
Net Earnings from Discontinued Operations 44 36 197 163
Net (Loss)/Earnings $(89) $(134) $2,165 $1,585
Earnings per Common Share
Basic:
Net (Loss)/Earnings from Continuing
Operations $(.07) $(.09) $1.00 $.73
Net Earnings from Discontinued
Operations .02 .02 .10 .08
Net (Loss)/Earnings per Common Share $(.05) $(.07) $1.10 $.81
Diluted:
Net (Loss)/Earnings from Continuing
Operations $(.07) $(.09) $.99 $.73
Net Earnings from Discontinued
Operations .02 .02 .10 .08
Net (Loss)/Earnings per Common Share $(.05) $(.07) $1.09 $.81
Average Common Shares Outstanding:
Basic 1,975 1,961 1,970 1,960
Diluted 1,975 1,961 1,980 1,963
(a) Other expense, net
Interest expense $97 $128 $422 $498
Interest income (57) (73) (241) (274)
Foreign exchange transaction losses 1 6 28 6
Other expense, net 290 179 155 69
$331 $240 $364 $299
APPENDIX 1
BRISTOL-MYERS SQUIBB COMPANY
DILUTED EARN
'/>"/>
SOURCE Bristol-Myers Squibb Company Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Related medicine news :1.
Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging2.
Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors3.
Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone4.
ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan5.
Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb6.
Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 257.
Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices8.
Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing9.
Bristol-Myers Squibb Announces Dividend10.
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company11.
First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II